证券代码：300357 证券简称：我武生物 公告编号：2025-039 号 浙江我武生物科技股份有限公司 关于 2025 年第三季度利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 审议程序 浙江我武生物科技股份有限公司（以下简称"公司"）于 2025年10月23日 召开了第五届董事会第十四次会议，以6票赞成、0票反对、0票弃权的表决结果 审议通过了《公司2025年第三季度利润分配的方案》。本次利润分配方案尚需提 交公司股东会审议。 二、 利润分配方案的基本情况 1. 本次利润分配为公司2025年第三季度利润分配。 2. 公司法定公积金累计额已超过公司注册资本的50%，根据《公司法》和 《公司章程》的相关规定，公司不再提取法定公积金。根据公司2025年第三季度 财务报表（未经审计），2025年1-9月合并报表归属于上市公司股东的净利润为 344,866,533.27 元 ； 截 至 2025 年 9 月 30 日 ， 公 司 合 并 报 表 未 分 配 利 润 1,713,212,446.57元，母公司报表未分配利润1,992,117, ...

我武生物公告，第三季度营收为3.69亿元，同比增长22.64%；净利润为1.68亿元，同比增长36.44%。前 三季度营收为8.53亿元，同比增长16.86%；净利润为3.45亿元，同比增长26.67%。 ...

浙江我武生物科技股份有限公司 2025 年第三季度报告 3.第三季度财务会计报告是否经过审计 浙江我武生物科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 证券代码：300357 证券简称：我武生物 公告编号：2025-038 □是 否 1 浙江我武生物科技股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 增减 | | 上年同期增减 | | 营业收入（元） | 369,123,847.45 | 22.64% ...

融券方面，我武生物10月22日融券偿还2100.00股，融券卖出1100.00股，按当日收盘价计算，卖出金额 3.48万元；融券余量10.20万股，融券余额322.63万元，超过近一年90%分位水平，处于高位。 分红方面，我武生物A股上市后累计派现9.13亿元。近三年，累计派现3.17亿元。 10月22日，我武生物跌3.18%，成交额3.23亿元。两融数据显示，当日我武生物获融资买入额3893.00万 元，融资偿还5399.65万元，融资净买入-1506.65万元。截至10月22日，我武生物融资融券余额合计4.30 亿元。 机构持仓方面，截止2025年6月30日，我武生物十大流通股东中，招商国证生物医药指数A（161726） 位居第五大流通股东，持股469.01万股，相比上期减少18.80万股。香港中央结算有限公司位居第七大流 通股东，持股410.96万股，相比上期减少49.18万股。创新药（159992）退出十大流通股东之列。 融资方面，我武生物当日融资买入3893.00万元。当前融资余额4.27亿元，占流通市值的2.58%，融资余 额超过近一年60%分位水平，处于较高位。 责任编辑：小浪快报 资料显示，浙 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Investment Rating - The report maintains a positive outlook on the innovative drug and medical device industry, highlighting key targets for investment [5][24]. Core Insights - The innovative drug sector is experiencing high growth, with a focus on companies such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, and others. The report emphasizes the potential for value re-evaluation in these firms [5][24]. - Recent business development (BD) deals in the innovative drug sector are expected to catalyze market activity, with notable transactions including Jiangsu Heng Rui Medicine's agreement with Kite for a $1.20 billion upfront payment, potentially reaching $15.20 billion in total [5][24]. - The A-share pharmaceutical sector underperformed the broader market in the third week of October 2025, with the Shanghai Composite Index falling by 1.5% and the SW Biopharma index declining by 2.5% [7][18]. Summary by Sections 1. Continuous Focus on Innovative Drugs and Medical Devices - The report emphasizes the high growth potential in innovative drugs, with key investment targets including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, and others. Related targets include CSPC Innovation Pharmaceutical [5][24]. 2. A-Share Pharmaceutical Sector Performance - In the third week of October 2025, the A-share pharmaceutical sector saw a decline of 2.5%, underperforming the Shanghai Composite Index, which fell by 1.5%. The report notes that the sector's premium relative to all A-shares is currently at a normal level, with a relative premium rate of 74.5% [7][14][21]. 3. Hong Kong and U.S. Pharmaceutical Sector Performance - The report indicates that the Hong Kong and U.S. pharmaceutical sectors also underperformed, with the Hang Seng Healthcare index dropping by 5.8% and the S&P 500 Healthcare index increasing by only 0.7% during the same period [18][24].

10月20日，我武生物涨10.07%，成交额7.37亿元。两融数据显示，当日我武生物获融资买入额9796.48 万元，融资偿还6928.49万元，融资净买入2867.99万元。截至10月20日，我武生物融资融券余额合计 4.38亿元。 融资方面，我武生物当日融资买入9796.48万元。当前融资余额4.35亿元，占流通市值的2.53%，融资余 额超过近一年70%分位水平，处于较高位。 截至6月30日，我武生物股东户数3.46万，较上期减少3.53%；人均流通股13999股，较上期增加3.66%。 2025年1月-6月，我武生物实现营业收入4.84亿元，同比增长12.81%；归母净利润1.77亿元，同比增长 18.61%。 分红方面，我武生物A股上市后累计派现9.13亿元。近三年，累计派现3.17亿元。 机构持仓方面，截止2025年6月30日，我武生物十大流通股东中，招商国证生物医药指数A（161726） 位居第五大流通股东，持股469.01万股，相比上期减少18.80万股。香港中央结算有限公司位居第七大流 通股东，持股410.96万股，相比上期减少49.18万股。创新药（159992）退出十大流通股东之列。 责 ...

Core Points - The Bioeconomy Index (970038) closed at 2262.82 points, up 0.08%, with a trading volume of 19.253 billion yuan and a turnover rate of 1.3% [1] - Among the index constituents, 27 stocks rose, with Iwubio leading at a 10.07% increase, while 22 stocks fell, with Yifan Pharmaceutical leading the decline at 4.45% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 223.47, down 0.90%, and a market cap of 270.944 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 121.12, down 0.12%, and a market cap of 49.409 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 30.56, up 1.76%, and a market cap of 54.342 billion yuan [1] - Shizhu Aoshi (sz002252) with a weight of 4.52%, latest price at 6.67, up 0.15%, and a market cap of 44.275 billion yuan [1] - Biao Ge Shi Medicine (sz300347) with a weight of 4.23%, latest price at 54.08, up 0.95%, and a market cap of 46.564 billion yuan [1] - Shenzhen Technology (sz000021) with a weight of 4.08%, latest price at 27.24, down 0.58%, and a market cap of 42.693 billion yuan [1] - Muyuan Foods (sz002714) with a weight of 3.66%, latest price at 49.48, down 2.25%, and a market cap of 270.298 billion yuan [1] - Aimeike (sz300896) with a weight of 3.44%, latest price at 167.03, down 1.49%, and a market cap of 50.542 billion yuan [1] - Kailai Ying (sz002821) with a weight of 3.23%, latest price at 105.80, up 2.72%, and a market cap of 38.151 billion yuan [1] - Color Egg Therapy (sz002223) with a weight of 3.19%, latest price at 36.65, down 1.24%, and a market cap of 36.741 billion yuan [1] Capital Flow Summary - The Bioeconomy Index constituents experienced a net outflow of 599 million yuan from institutional investors and 215 million yuan from retail investors, while retail investors saw a net inflow of 814 million yuan [3] - Notable capital flows include: - Kanglong Chemical saw a net inflow of 74.766 million yuan from institutional investors, while retail investors experienced a net outflow of 49.703 million yuan [3] - Hualan Biological had a net inflow of 42.164 million yuan from institutional investors, with retail investors seeing a net outflow of 33.5328 million yuan [3] - Lepu Medical had a net inflow of 40.927 million yuan from institutional investors, while retail investors had a net outflow of 32.1814 million yuan [3] - Kailai Ying had a net inflow of 38.867 million yuan from institutional investors, with retail investors experiencing a net outflow of 16.4533 million yuan [3] - Iwubio had a net inflow of 23.192 million yuan from institutional investors, while retail investors saw a net outflow of 5.9208 million yuan [3]

Core Insights - The biopharmaceutical sector experienced a slight increase of 0.14% on October 20, with Iwu Biologics leading the gains [1] - The Shanghai Composite Index closed at 3863.89, up 0.63%, while the Shenzhen Component Index closed at 12813.21, up 0.98% [1] Biopharmaceutical Sector Performance - Iwu Biologics (300357) saw a significant rise of 10.07%, closing at 32.90 with a trading volume of 228,200 shares and a transaction value of 737 million [1] - Other notable gainers included Olin Biologics (6168889) with a 4.58% increase, closing at 23.96, and Kangchen Pharmaceutical (603590) with a 4.00% increase, closing at 51.19 [1] - The sector also had some underperformers, such as Novavax (688105) which fell by 3.56%, closing at 21.96 [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 239 million from institutional investors, while retail investors saw a net inflow of 270 million [2] - The data indicates that retail investors are actively buying into the sector despite the overall net outflow from larger institutional players [2] Individual Stock Capital Flow - Iwu Biologics had a net inflow of 23.19 million from institutional investors, while it faced a net outflow of 17.27 million from speculative funds [3] - Notably, Huashan Biologics (002007) had a net inflow of 42.16 million from institutional investors, indicating strong institutional interest [3]

Market Overview - The Shanghai Composite Index closed at 3866.09 points, below the five-day moving average, with a change of 0.69% [1] - The total trading volume of A-shares reached 1,170.861 billion yuan [1] Stocks Performance - A total of 1,088 A-shares have surpassed the five-day moving average today [1] - Stocks with significant deviation rates include: - Haike Xinyuan (14.44%) - Huarui Co., Ltd. (13.38%) - Zhongwei Electronics (10.11%) [1] Notable Stocks - Top stocks with the highest deviation rates from the five-day moving average: - Haike Xinyuan: Today's change of 19.98%, latest price 31.22 yuan, five-day moving average 27.28 yuan [1] - Huarui Co., Ltd.: Today's change of 20.00%, latest price 12.66 yuan, five-day moving average 11.17 yuan [1] - Zhongwei Electronics: Today's change of 20.00%, latest price 12.42 yuan, five-day moving average 11.28 yuan [1] Additional Stocks - Other notable stocks with positive performance: - Zhuhai Guanyu: Change of 13.88%, latest price 25.52 yuan, five-day moving average 23.35 yuan [1] - Feiwo Technology: Change of 18.35%, latest price 45.15 yuan, five-day moving average 41.36 yuan [1] - Hui Green Ecology: Change of 10.02%, latest price 16.25 yuan, five-day moving average 14.97 yuan [1]